Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ruobin Lin
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Sun Yat-sen University,
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
ORCID:
0009-0002-9789-6159
Observed ORCID:
0009-0002-9789-6159
OpenAlex ID:
A5058565261
De-escalated surgery following neoadjuvant chemoimmunotherapy for locally advanced oral squamous cell carcinoma: A retrospective cohort study
2025
·
Fei Cao
, Qi Fang
, et al.
·
Oral Oncology
·
27
Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025
·
Fei Cao
, Yan Li
, et al.
·
Clinical Cancer Research
·
10
omitting neck dissection in cT3-4N0M0 oral squamous cell carcinoma with Imaging-Negative nodes after neoadjuvant chemoimmunotherapy: A retrospective cohort study
2026
·
Qi Fang
, Fei Cao
, et al.
·
Oral Oncology
·
2
[Clinical application of inflatable unilateral axillary approach robot assisted bilateral thyroid lobe lesion resection].
2025
·
Di Wu
, Zheng Zhao
, et al.
·
PubMed
[Progress in the application of robotic technology in thyroid surgery].
2025
·
Di Wu
, Zheng Zhao
, et al.
·
PubMed
Supplement 4 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025
·
Fei Cao
, Yan Li
, et al.
Data from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025
·
Fei Cao
, Yan Li
, et al.
Supplement 2 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025
·
Fei Cao
, Yan Li
, et al.
Supplement 5 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025
·
Fei Cao
, Yan Li
, et al.
Supplement 1 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025
·
Fei Cao
, Yan Li
, et al.
Supplement 3 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025
·
Fei Cao
, Yan Li
, et al.
Show more works
View as search
Works count:
11
Citation count:
39
H-index:
2
I10-index:
2
Year
Topic
Type